Safety, immunology, and biological activity evaluation of TroVax in treatment of patients with locally advanced or metastatic renal carcinoma

Trial Profile

Safety, immunology, and biological activity evaluation of TroVax in treatment of patients with locally advanced or metastatic renal carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2008

At a glance

  • Drugs Interleukin-2; MVA 5T4
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Oxford BioMedica
  • Most Recent Events

    • 31 Jul 2008 The actual completion date for this trial was 1 July 2008.
    • 31 Jul 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
    • 02 Jun 2008 Results presented at the American Society of Clinical Oncology (ASCO) annual meeting in 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top